asciminib BCR-ABL1 Fusion, +1 more biomarker Chronic Myeloid Leukemia Chronic phase Subsequent line asciminib targeted therapy
dasatinib + chemotherapy BCR-ABL1 Fusion, +1 more biomarker Acute Lymphoblastic Leukemia Newly diagnosed chemotherapy, +1 more drug chemotherapy, +1 more type
nilotinib BCR-ABL1 Fusion, +1 more biomarker Chronic Myeloid Leukemia Chronic phase Subsequent line nilotinib targeted therapy
bosutinib BCR-ABL1 Fusion, +1 more biomarker Chronic Myeloid Leukemia Chronic phase, +1 more state bosutinib targeted therapy
dasatinib BCR-ABL1 Fusion, +1 more biomarker Chronic Myeloid Leukemia Chronic phase dasatinib targeted therapy
imatinib + chemotherapy BCR-ABL1 Fusion, +1 more biomarker Acute Lymphoblastic Leukemia Newly diagnosed chemotherapy, +1 more drug chemotherapy, +1 more type
bosutinib BCR-ABL1 Fusion, +1 more biomarker Chronic Myeloid Leukemia Accelerated phase, +2 more states Subsequent line bosutinib targeted therapy
dasatinib BCR-ABL1 Fusion, +1 more biomarker Chronic Myeloid Leukemia Chronic phase, +1 more state dasatinib targeted therapy
nilotinib BCR-ABL1 Fusion, +1 more biomarker Chronic Myeloid Leukemia Chronic phase, +1 more state nilotinib targeted therapy
nilotinib BCR-ABL1 Fusion, +1 more biomarker Chronic Myeloid Leukemia Accelerated phase, +1 more state Subsequent line nilotinib targeted therapy
imatinib BCR-ABL1 Fusion, +1 more biomarker Acute Lymphoblastic Leukemia Relapse/refractory imatinib targeted therapy
Cancer Search
